Mario Giovanni Chilelli

Five years survival in metastatic non‐small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial

Paolo Lissoni, Mario Giovanni Chilelli, S. Villà et al. · Journal of Pineal Research · 2003 · 207 citations

A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first‐line treatment of advanced non‐small cell lung cancer patients in a poor clinical state

Paolo Lissoni, Franco Paolorossi, Antonio Ardizzoia et al. · Journal of Pineal Research · 1997 · 113 citations

Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial

Sabino De Placido, Ciro Gallo, Michelino De Laurentiis et al. · The Lancet Oncology · 2018 · 86 citations · Full text

Endocrine Oncology, Breast Oncology, Medicine +7

Prognostic factors for chemotherapy response and survival using combination chemotherapy as initial treatment of advanced head and neck squamous cell cancer.

F. Cognetti, Paola Pinnarò, Enzo Maria Ruggeri et al. · Journal of Clinical Oncology · 1989 · 79 citations

World Health Organization, Surgical Oncology, Neoadjuvant Therapy +19

A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients

Paolo Lissoni, Franco Paolorossi, Gabriele Tancini et al. · British Journal of Cancer · 1996 · 57 citations · Full text

Oncology, Medicine, Phase Ii Study +9